XFORHealthcare · BiotechnologyThe 5 Wall Street analysts covering X4 Pharmaceuticals, Inc. hold a median 12-month price target of $12 — +196.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 63 of 100 as at 22 Aug 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores X4 Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (90): Analysts have, on balance, been raising their forecasts.
Volatility (28): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on XFOR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +196.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 10 July 2026 | Wells Fargo | Initiates | Overweight | $11 |
| 2 June 2026 | Leerink Partners | Initiates | Outperform | — |
| 9 Mar 2026 | Guggenheim | Initiates | Buy | — |
| 5 Dec 2025 | Stifel | Maintains | Buy | — |
| 10 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 29 Aug 2025 | Stifel | Maintains | Buy | — |
| 13 Aug 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 2 May 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 27 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 26 Mar 2025 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 7 Feb 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 Nov 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 14 Nov 2024 | Stifel | Maintains | Buy | — |
| 28 June 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 31 May 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 30 Apr 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 22 Mar 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 12 Dec 2023 | B. Riley Securities | Downgrade | Neutral | — |
| 11 Aug 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. XFOR appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 24 Aug 2026, X4 Pharmaceuticals, Inc. returned +3.3% against +19.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 69% of US stocks
Cheaper than 8% of US stocks
Cheaper than 40% of US stocks
Cheaper than 75% of US stocks
Higher than 97% of US stocks
Higher than 92% of US stocks
Higher than 11% of US stocks
Higher than 99% of US stocks
Higher than 12% of US stocks
Higher than 15% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
X4 Pharmaceuticals, Inc. has a market value of $400.6M and an enterprise value of $269.8M.
Revenue in the twelve months to 30 June 2026: $15.8M. The latest quarter grew 346.3% year on year.
Net income over the same four quarters: −$90.1M, a −568.8% net margin.
Free cash flow in the twelve months to 30 June 2026: −$88.7M.
Trailing P/E: 2.8×; forward P/E: −5.4× — the forward figure prices analyst consensus estimates, not reported earnings.
X4 Pharmaceuticals, Inc. employs 45 people — $352K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own X4 Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
X4 Pharmaceuticals (XFOR) was upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about its earnings prospects.
Why it matters — A XFOR watcher would care because the upgrade signals improving expectations for the company's earnings outlook.
X4 Pharmaceuticals reported a Q2 loss of $0.13 per share, which was narrower than the Zacks Consensus Estimate of a $0.19 loss and an improvement from the $3.47 per share loss a year earlier. The company's results beat revenue estimates.
Why it matters — A narrower-than-expected quarterly loss and revenue beat indicate improving financial performance for XFOR watchers.
X4 Pharmaceuticals reported its financial results for the second quarter ended June 30, 2026 and provided a corporate update on August 6, 2026. The company focuses on improving the lives of people with rare hematology diseases.
Why it matters — The quarterly financial results and corporate update provide XFOR watchers with an official update on the company's recent performance and business progress.
X4 Pharmaceuticals announced that, effective July 31, 2026, it issued inducement awards to new employees under its 2019 Inducement Equity Incentive Plan. The awards comprise options to purchase an aggregate of 12,000 shares of common stock, granted as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4) and approved by the company's Compensation Committee.
Why it matters — A XFOR watcher would care as this routine equity-grant disclosure signals the onboarding of new employees under the company's inducement plan, a standard corporate action in line with Nasdaq rules.
The 5 Wall Street analysts covering X4 Pharmaceuticals, Inc. have a median 12-month price target of $12, with estimates ranging from $10 to $13. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 5 analysts covering X4 Pharmaceuticals, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks X4 Pharmaceuticals, Inc. 63 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, X4 Pharmaceuticals, Inc. ranks 63 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (90 of 100).
No one can know that. What the data says: the median 12-month target from 5 analysts implies +196.3% from the last close, and Ticker Nerd's factor model ranks X4 Pharmaceuticals, Inc. 63 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering X4 Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for XFOR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $13 over the next 12 months.
X4 Pharmaceuticals, Inc. returned +3.3% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
X4 Pharmaceuticals Inc. is a biopharmaceutical company focused on the research, development, and commercialization of novel therapeutics targeting rare diseases of the immune system and rare hematology diseases.
The most recent item we track (Zacks Investment Research, 11 Aug 2026): "X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's Why". X4 Pharmaceuticals (XFOR) was upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about its earnings prospects.
X4 Pharmaceuticals Inc. is a biopharmaceutical company focused on the research, development, and commercialization of novel therapeutics targeting rare diseases of the immune system and rare hematology diseases. Its lead product, XOLREMDI (mavorixafor), is an orally bioavailable selective antagonist of the chemokine receptor CXCR4, approved in the United States for treating patients with warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome by mobilizing functional white blood cells from the bone marrow into circulation. The company is advancing mavorixafor in the ongoing Phase 3 4WARD clinical trial, evaluating its efficacy, safety, and tolerability, with or without G-CSF, in patients with congenital, acquired primary autoimmune, or idiopathic chronic neutropenia who suffer recurrent or serious infections. X4 Pharmaceuticals Inc. leverages expertise in CXCR4 pathway biology to address unmet needs in conditions characterized by low neutrophil counts and heightened infection risks. Headquartered in Boston, Massachusetts, the company maintains license agreements for mavorixafor development in oncology combinations and specific geographic regions outside the U.S.
CEO Dr. Paula Ragan Ph.D. · 45 employees · United States · https://www.x4pharma.com
